Table 2:

The time (in years) it takes for the last-line treatment of gonorrhea to reach 95% (denoted by τ₉₅), and 90% (denoted by τ₉₀) effectiveness as well as the time at which this treatment ceases to be economical (i.e., τ*). The last row indicates the annualized total cost of gonorrhea per person (ρv*) for an infinite time horizon when the discount rate ρ is 3%. All policy-relevant quantities were evaluated with an initial gonorrhea prevalence of 0.27% and drug quality of 99.6%. The range corresponds to 2.5% and 97.5% quantiles of each quantity.

Policy Relevant Quantities	Base Value	Range	Description
τ95	9.53	4.75 – 19.09	Years until drug quality reduces to 95%
τ90	12.30	6.13 – 24.63	Years until drug quality reduces to 90%
τ*	30.31	14.11 – 61.79	Years until treatment is no longer economical (optimal stopping time)
ρv*	$28.19	$6.34 – $46.38	Annualized per-person cost of gonorrhea under the optimal policy